Korro to Participate in Upcoming Investor and Scientific Conferences
Korro Bio (Nasdaq: KRRO) has announced its participation in six major investor and scientific conferences during September 2025. The company's leadership team, including CEO Ram Aiyar, CSO Loic Vincent, CFO Vineet Agarwal, and COO Todd Chappell, will engage in various activities across these events.
Key events include presentations at the Cantor Global Healthcare Conference and the RNA Leaders USA Congress, where they will discuss RNA editing therapies. The management team will also conduct one-on-one investor meetings at multiple conferences, including Citi's Biopharma Back to School Conference, Wells Fargo Securities Healthcare Conference, H.C. Wainwright Global Investment Conference, and Morgan Stanley Global Healthcare Conference.
Korro Bio (Nasdaq: KRRO) ha annunciato la partecipazione a sei importanti conferenze per investitori e ambito scientifico nel settembre 2025. Il team dirigente, composto dal CEO Ram Aiyar, dal CSO Loic Vincent, dal CFO Vineet Agarwal e dal COO Todd Chappell, prender脿 parte a diverse attivit脿 durante questi eventi.
Tra gli appuntamenti principali figurano gli interventi al Cantor Global Healthcare Conference e al RNA Leaders USA Congress, dove verranno trattate terapie basate sull'editing dell'RNA. Il management terr脿 inoltre incontri one鈥憈o鈥憃ne con investitori in pi霉 congressi, tra cui il Citi Biopharma Back to School Conference, il Wells Fargo Securities Healthcare Conference, l'H.C. Wainwright Global Investment Conference e il Morgan Stanley Global Healthcare Conference.
Korro Bio (Nasdaq: KRRO) ha anunciado su participaci贸n en seis importantes conferencias para inversores y del 谩mbito cient铆fico durante septiembre de 2025. El equipo directivo, integrado por el CEO Ram Aiyar, el CSO Loic Vincent, el CFO Vineet Agarwal y el COO Todd Chappell, participar谩 en diversas actividades a lo largo de estos eventos.
Entre los eventos clave se encuentran presentaciones en el Cantor Global Healthcare Conference y en el RNA Leaders USA Congress, donde abordar谩n las terapias de edici贸n de ARN. Adem谩s, la direcci贸n mantendr谩 reuniones individuales con inversores en varios congresos, incluidos el Citi Biopharma Back to School Conference, el Wells Fargo Securities Healthcare Conference, el H.C. Wainwright Global Investment Conference y el Morgan Stanley Global Healthcare Conference.
Korro Bio (Nasdaq: KRRO)電� 2025雲� 9鞗旍棎 臧滌禍霅橂姅 欤检殧 韴瀽鞛惵讽暀靾� 旎嵓霟办姢 6瓿踌棎 彀戈皜頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. CEO Ram Aiyar, CSO Loic Vincent, CFO Vineet Agarwal, COO Todd Chappell 霌� 瓴届榿歆勳澊 臧� 頄夓偓鞐愳劀 雼れ枒頃� 頇滊彊鞚� 歆勴枆頃� 鞓堨爼鞛呺媹雼�.
欤检殧 鞚检爼鞙茧電� Cantor Global Healthcare Conference鞕赌 RNA Leaders USA Congress鞐愳劀鞚� 氚滍憸臧� 韽暔霅橂┌, 鞐赴靹� RNA 韼胳 旃橂氩曥棎 雽�頃� 雲检潣頃� 鞓堨爼鞛呺媹雼�. 霕愴暅 瓴届榿歆勳潃 Citi Biopharma Back to School Conference, Wells Fargo Securities Healthcare Conference, H.C. Wainwright Global Investment Conference, Morgan Stanley Global Healthcare Conference 霌� 鞐煬 須岇潣鞐愳劀 鞚茧寑鞚� 韴瀽鞛� 氙疙寘霃� 臧�歆� 鞓堨爼鞛呺媹雼�.
Korro Bio (Nasdaq: KRRO) a annonc茅 sa participation 脿 six grandes conf茅rences d'investisseurs et scientifiques en septembre 2025. L'茅quipe dirigeante, comprenant le CEO Ram Aiyar, le CSO Loic Vincent, le CFO Vineet Agarwal et le COO Todd Chappell, prendra part 脿 diverses activit茅s lors de ces 茅v茅nements.
Parmi les rendez鈥憊ous cl茅s figurent des pr茅sentations au Cantor Global Healthcare Conference et au RNA Leaders USA Congress, o霉 seront abord茅es les th茅rapies d'茅dition de l'ARN. La direction tiendra 茅galement des r茅unions individuelles avec des investisseurs lors de plusieurs conf茅rences, notamment le Citi Biopharma Back to School Conference, le Wells Fargo Securities Healthcare Conference, le H.C. Wainwright Global Investment Conference et le Morgan Stanley Global Healthcare Conference.
Korro Bio (Nasdaq: KRRO) hat seine Teilnahme an sechs gro脽en Investoren- und wissenschaftlichen Konferenzen im September 2025 angek眉ndigt. Das F眉hrungsteam, bestehend aus CEO Ram Aiyar, CSO Loic Vincent, CFO Vineet Agarwal und COO Todd Chappell, wird an verschiedenen Programmpunkten dieser Veranstaltungen teilnehmen.
Zu den wichtigsten Terminen geh枚ren Pr盲sentationen auf der Cantor Global Healthcare Conference und dem RNA Leaders USA Congress, bei denen RNA鈥慐diting鈥慣herapien thematisiert werden. Dar眉ber hinaus f眉hrt das Management Einzelgespr盲che mit Investoren auf mehreren Konferenzen, darunter das Citi Biopharma Back to School Conference, das Wells Fargo Securities Healthcare Conference, das H.C. Wainwright Global Investment Conference und das Morgan Stanley Global Healthcare Conference.
- None.
- None.
CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor and scientific conferences for the month of September:
Citi's 2025 Biopharma Back to School Conference
Ram Aiyar, Ph.D., Chief Executive Officer and President, and Loic Vincent, Ph.D., Chief Scientific Officer, will participate in 1x1 investor meetings on Wednesday, September 3, 2025.
Cantor Global Healthcare Conference
Dr. Aiyar will participate in a fireside chat on Thursday, September 4, 2025, at 3:55 p.m. ET. Vineet Agarwal, Chief Financial Officer, will also participate in 1x1 investor meetings at the conference.
2025 Wells Fargo Securities Healthcare Conference
Dr. Vincent and Todd Chappell, Chief Operating Officer, will participate in 1x1 investor meetings on Friday, September 5, 2025.
H.C. Wainwright 27th Annual Global Investment Conference
Mr. Agarwal and Mr. Chappell will participate in 1x1 investor meetings on Monday, September 8, 2025.
Morgan Stanley 23rd Annual Global Healthcare Conference
Mr. Agarwal and Mr. Chappell will participate in 1x1 investor meetings on Monday, September 8, 2025.
RNA Leaders USA Congress
Mr. Chappell will deliver a presentation titled, 鈥淒eveloping Novel RNA Editing Therapies to Address Unmet Needs for Rare and Highly Prevalent Diseases,鈥� on Thursday, September 11, 2025, at 11:45 a.m. ET.
About Korro
Korro is a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases. Korro is generating a portfolio of differentiated programs that are designed to harness the body鈥檚 natural RNA editing process, enabling a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.
Korro intends to use its Investor Relations website, LinkedIn, and X (Twitter) as means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Korro鈥檚 Investor Relations website and follow @KorroBio on LinkedIn, and X (Twitter), in addition to following Korro鈥檚 press releases, SEC filings, public conference calls, presentations, and webcasts.聽
Korro Bio Contact Information
Investors
滨搁蔼办辞谤谤辞产颈辞.肠辞尘听
Media
Glenn Silver聽
FINN Partners聽
骋濒别苍苍.蝉颈濒惫别谤蔼蹿颈苍苍辫补谤迟苍别谤蝉.肠辞尘听
This press release was published by a CLEAR庐 Verified individual.
FAQ
When is Korro Bio (KRRO) presenting at the Cantor Global Healthcare Conference 2025?
What will be the topic of Korro Bio's presentation at the RNA Leaders USA Congress 2025?
Which Korro Bio executives are participating in the Morgan Stanley Healthcare Conference 2025?
How many conferences is Korro Bio (KRRO) attending in September 2025?
